IRIS
BIANCO, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.773
EU - Europa 1.952
AS - Asia 890
AF - Africa 74
SA - Sud America 4
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 5.697
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.722
IT - Italia 1.023
SG - Singapore 453
CN - Cina 326
UA - Ucraina 206
NL - Olanda 168
IE - Irlanda 131
DE - Germania 130
FI - Finlandia 120
CI - Costa d'Avorio 73
FR - Francia 51
SE - Svezia 50
CA - Canada 49
GB - Regno Unito 40
IN - India 39
VN - Vietnam 30
PK - Pakistan 21
BE - Belgio 6
ES - Italia 5
IR - Iran 5
BG - Bulgaria 4
JO - Giordania 4
RU - Federazione Russa 4
GR - Grecia 3
HK - Hong Kong 3
MY - Malesia 3
SI - Slovenia 3
AU - Australia 2
CL - Cile 2
CZ - Repubblica Ceca 2
TR - Turchia 2
AP - ???statistics.table.value.countryCode.AP??? 1
AR - Argentina 1
AT - Austria 1
BD - Bangladesh 1
BZ - Belize 1
CH - Svizzera 1
DK - Danimarca 1
EC - Ecuador 1
EG - Egitto 1
EU - Europa 1
JP - Giappone 1
KR - Corea 1
MK - Macedonia 1
MX - Messico 1
PL - Polonia 1
RS - Serbia 1
UZ - Uzbekistan 1
Totale 5.697
Salva come PNG Salva come JPEG
Città #
Chandler 484
Singapore 366
Jacksonville 234
Napoli 189
Naples 176
Amsterdam 164
Millbury 153
Ashburn 134
Princeton 115
Santa Clara 114
Beijing 84
Nanjing 73
Boston 69
Wilmington 59
Woodbridge 54
Ottawa 47
Des Moines 43
Rome 36
Nanchang 35
Dong Ket 28
Pune 25
Hebei 24
Houston 24
Hicksville 23
Shenyang 23
Boardman 20
Caserta 20
Lawrence 19
Norwalk 19
Ann Arbor 18
Milan 17
Jiaxing 15
Redwood City 14
Islamabad 13
Tianjin 13
Kronberg 12
San Mateo 12
Munich 11
Seattle 11
Changsha 10
Falls Church 8
Formia 8
Modica 8
Salerno 8
Villarosa 8
Washington 8
Casoria 7
Palma Campania 7
Rozzano 7
Shanghai 7
Indiana 6
Angri 5
Lahore 5
Leawood 5
Nürnberg 5
Turin 5
Amman 4
Augusta 4
Dallas 4
Florence 4
Fucecchio 4
Kolkata 4
Los Angeles 4
Menfi 4
Portici 4
Siena 4
Sofia 4
Villaricca 4
Afragola 3
Ardabil 3
Caivano 3
Casagiove 3
Castel San Giovanni 3
Dearborn 3
Dublin 3
Helsinki 3
Hong Kong 3
Lanzhou 3
Latina 3
Menlo Park 3
Monte Di Procida 3
Moscow 3
Pizzo 3
Pomigliano d'Arco 3
Pozzuoli 3
Salt Lake City 3
Serravalle Scrivia 3
Veroli 3
Yellow Springs 3
Andria 2
Aversa 2
Bari 2
Bologna 2
Brussels 2
Castellammare Di Stabia 2
Catania 2
Changchun 2
Chengdu 2
Duncan 2
Edegem 2
Totale 3.240
Salva come PNG Salva come JPEG
Nome #
null 223
Epigenetic silencing of THY1 tracks the acquisition of the Notch1-EGFR signaling in a xenograft model of CD44+/CD24low/CD90+ myoepithelial cells 93
Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors 92
The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity 88
Studio dei meccanismi autocrini e paracrini di attivazione di Hedgehog in modelli tumorali umani. 78
Development of 1,2,3-Triazole-Based Sphingosine Kinase Inhibitors and Their Evaluation as Antiproliferative Agents 74
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 73
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers 67
Association of FGFR1 with ERαmaintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer 63
C-Src and EGFR inhibition in molecular cancer therapy: What else can we improve? 63
AXL is an oncotarget in human colorectal cancer 62
1599P - Effects of Hedgehog signaling inhibition on epithelial-stromal interactions in triple negative breast cancer cells 57
Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models 56
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 55
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status 53
Rationale and design of MILES-3 and MILES-4 studies: two randomized phase III trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non-small cell lung cancer 52
ANTITUMOR ACTIVITY OF ZD6474, A VEGFR-2 AND EGFR SMALL MOLECULE TYROSINE KINASE INHIBITOR, IN COMBINATION WITH SC-236, A CYCLOOXYGENASE-2 INHIBITOR. 52
A novel mdm2 antisense oligonucleotide has antitumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. 52
Addition of erlotinib to fluoropyrimidine-oxaliplatin-basedchemotherapy with or without bevacizumab: Two sequential phase I trials 52
The Impact of Translational Research in Breast Cancer Care: Can We Improve the Therapeutic Scenario? 52
Paraneoplastic sensitive neuropathy associated with anti-hu antibodies in a neuroendocrine tumor of duodenum: a case report. 51
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. 50
Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling. 50
Enzastaurin inhibits tumors sensitive and resistant to anti-EGFR drugs 50
Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to anti-epidermal growth factor receptor antibody 50
Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. 48
The Epithelial-Stromal Interaction as a Potential Target for Breast Cancer Treatment 48
From biology to therapy: Improvements of therapeutic options in Lung cancer 48
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 48
Combination of biological therapies in non-small cell lung cancer. 47
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an EGFR-selective tyrosine kinase inhibitor. 47
Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis. 47
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 46
COMBINED TARGETING OF EGFR AND MDM2 BY GEFITINIB AND ANTISENSE MDM2 COOPERATIVELY INHIBIT HORMONE-INDEPENDENT PROSTATE CANCER. 46
Epidermal growth factor receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models. 46
Approaches for targeting cancer stem cells drug resistance 46
Mechanisms of resistance to mTOR inhibitors 46
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 46
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. 45
MONOCLONAL ANTIBODIES TARGETING THE EPIDERMAL GROWTH FACTOR RECEPTOR. 44
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. 44
Antitumor activity of combined treatment of human cancer cells with ionizing radiations and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. 44
Bevacizumab related arterial hypertension as a predictive marker in metastatic Colorectal Cancer (mCRC) patients 44
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells 44
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 44
Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. 43
Antiangiogenic and antitumor activity of anti-EGFR C225 monoclonal antibody in combination with Vascular Endothelial Growth Factor antisense oligonucleotide in human GEO colon cancer cells. 43
Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma. 43
Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. 43
Use of folfirinox or nab-paclitaxel plus gemcitabine for the treatment of locally advanced pancreatic adenocarcinoma: A single institution observational study 43
ANTITUMOR ACTIVITY OF THE COMBINATION OF CETUXIMAB, AN ANTI-EGFR BLOCKING MONOCLONAL ANTIBODY AND ZD6474, AN INHIBITOR OF VEGFR AND EGFR TYROSINE KINASES. 42
Everolimus induces Met inactivation by disrupting the FKBP12/Met complex 42
Capecitabine plus weekly oxaliplatin in gastrointestinal tumors: a phase I study. 41
A phase II study of beweekly oxaliplatin plus infusional 5fluorouracil and folinic acid (FOLFOX4) as first-line treatment of advenced gastric cancer patients 41
Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer 41
Mechanisms of lapatinib resistance in HER2-driven breast cancer 41
Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells. 40
Role of sphingosine kinase 1 (SphK1) on cetuximab resistance in colorectal cancer models 40
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents 40
A Novel Toll-Like Receptor 9 Agonist Cooperates with Trastuzumab in Trastuzumab-Resistant Breast Tumors through Multiple Mechanisms of Action 39
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part 39
The mechanisms of resistance to EGFR inhibitors. 38
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. 38
P0081 Src inhibitors act through different mechanisms to cooperate with EGFR or MEK inhibitors in NSCLC models sensitive or resistant to erlotinib 38
Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells 38
INTRINSIC AND ACQUIRED RESISTANCE TO EGFR INHIBITORS IN HUMAN CANCER THERAPY. 38
Novel TLR9 agonist induces EGFR inhibition and synergistic antitumor activity with EGFR inhibitors. 37
Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: tolerability, and prognostic factors. 37
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 36
Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy 36
Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. 36
Combined blockade of PKA and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis. 36
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. 36
MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1 36
Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors 36
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 36
Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: a systematic review 36
CHEMOSENSITIZATION BY ANTISENSE OLIGONUCLEOTIDES TARGETING MDM2. 35
Combined blockade of PKA and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis. 35
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. 35
Antitumor activity of ZD6474, a small molecule VEGF receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to EGF receptor-targeted drugs. 35
High-rsolution melting analysis (HRMA) for KRAS mutatiinal study in patients with metastatic colorectal cancer (mCRC pts) 35
Oxidative stress mediates the antiproliferative effects of nelfinavir in breast cancer cells 35
Key cancer cell signal transduction pathways as therapeutic targets. 34
Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. 34
Selective disruption of insulin-like growth factor-1 (IGF-1) signaling via phosphoinositide-dependent kinase-1 prevents the protective effect of IGF-1 on human cancer cell death. 34
Inhibition of growth factors production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. 33
Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease. 33
Thyroid-stimulating hormone-regulated growth and cell cycle distribution of thyroid cells involve type I isozime of cyclic AMP-dependent protein kinase. 33
Tumour microenvironment and immune evasion in EGFR addicted NSCLC: Hurdles and possibilities 33
TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. 32
Preliminary analysis of chemotheraphy-induced cardiotoxicity in breast cancer patients trated with Amifostine. 32
Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: A case report 32
Phosphatidylinositol 3-kinase (PI3Ka)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells 32
Oral antisense targeting protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis and growth factors production. 31
Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. 31
Correlation between bevacizumab-related hypertension and response in mCRC patients 30
SPHINGOSINE KINASE 1 (SPHK1) CONTRIBUTES TO RESISTANCE TO EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS IN COLORECTAL CANCER MODELS 30
Sphingosine Kinase 1 (SphK1) overespression contributes to cetuximab resistance in human colrectal cancer. 30
Predictors of outcomes in patients with EGFR-mutated non-small cell lung cancer receiving EGFR tyrosine kinase inhibitors: A systematic review and meta-analysis 30
Totale 4.629
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.943
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.943
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020359 0 0 0 0 81 26 12 10 4 50 71 105
2020/2021647 7 45 60 50 80 84 69 11 89 29 79 44
2021/2022871 16 1 11 25 12 25 11 29 154 73 206 308
2022/20231.270 143 103 46 87 143 148 7 121 198 179 57 38
2023/2024913 31 130 127 91 37 97 25 105 16 21 179 54
2024/2025698 224 240 14 91 129 0 0 0 0 0 0 0
Totale 5.961